Form 8-K Ultragenyx Pharmaceutica For: Oct 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE)
October 4, 2024 5:54 AM EDTLeerink Partners analyst Joseph Schwartz reiterated an Outperform rating and $85.00 price target on Ultragenyx Pharma (NASDAQ: RARE).
The analyst comments "Bottom Line: Ultragenyx provided an update on the Cyprus2+ study for UX701 in Wilson disease, with the company opting to add a higher dose cohort before moving to Stage 2; we do not view this program as a core focus for the stock (at least in the near term), with most attention set on the ORBIT readout with setrusumab. UX701 is an AAV9 gene therapy in development for the treatment of Wilson disease, a... More
